Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3
- 776 Downloads
Nicotine, a main addictive compound in tobacco smoke, has been linked to promotion and progression of lung, head and neck, pancreatic, and breast cancers, but the detailed mechanisms of cancer progression remain elusive. Here, we show that nicotine induces the expression of galectin-3 (an anti-apoptotic β-galactoside-binding lectin) in breast cancer cell line and in primary tumors from breast cancer patients. Nicotine-induced up regulation of galectin-3 is due to an increased expression of α9 isoform of nicotinic acetylcholine receptor (α9nAChR), which activates transcription factor STAT3 that in turn, physically binds to galectin-3 (LGALS3) promoter and induces transcription of galectin-3. Intracellular galectin-3 increased mitochondrial integrity and suppressed chemotherapeutic-induced apoptosis of breast cancer cell. Moreover, nicotine-induced enrichment of side population cells with cancer stem cell-like properties was modulated by galectin-3 expression and could be significantly reduced by transient knock down of LGALS3 and its upstream signaling molecules STAT3 and α9nAChR. Thus, galectin-3 or its upstream signaling molecule STAT3 or α9nAChR could be a potential target to prevent nicotine-induced chemoresistance in breast cancer.
KeywordsNicotine Apoptosis Metastatic cancer Stem cell Galectin-3
α9 isoform of nicotinic acetylcholine receptor
We are grateful to Dr. Aditi Banerjee for her help on the scratch-wound healing assay. This study was supported by the University of Maryland Start-up fund and in part by the NIH Grants RO3CA133935 and R41CA141970 to H.A; and R01CA105005 and Cigarette Restitution Funds from the University of Maryland Greenebaum Cancer Center to D.V.K.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Adhikari B, Kahende J, Malarcher A, Pechacek T, Tong V (2008) Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. Morbidity and Mortality Weekly Rep 2008, 57:1226–1228 Google Scholar
- 6.Shih YL, Liu HC, Chen CS, Hsu CH, Pan MH, Chang HW, Chen FC, Ho CT, Yang YY, Ho YS (2010) Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down regulating nicotinic acetylcholine receptors. J Agric Food Chem 58:235–241PubMedCrossRefGoogle Scholar
- 8.Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T et al (2009) Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 101:967–972PubMedCentralPubMedCrossRefGoogle Scholar
- 16.Guha P, Kaptan E, Bandypadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DK, Vasta GR, Ahmed H (2013) Cod glycopeptides with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci USA 110:5052–5057PubMedCentralPubMedCrossRefGoogle Scholar
- 21.Lotz MM, Andrews CW Jr, Korzeliu CA, Lee EC, Steele GD Jr, Clarke A, Mercurio AM (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466–3470PubMedCentralPubMedCrossRefGoogle Scholar
- 28.Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV (2009) Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11:901–909PubMedCentralPubMedGoogle Scholar
- 31.Ahmed H, Cappello F, Rodolico V, Vasta GR (2009) Evidence of heavy methylation in the galectin-3 promoter in early stages of prostate-adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2:146–156PubMedCentralPubMedCrossRefGoogle Scholar
- 33.Sierra J, Villagra A, Paredes R, Cruzat F, Gutierrez S, Javed A, Arriagada G, Olate J, Imschenetzky M, Van Wijnen AJ et al (2003) Regulation of bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 23:3339–3351PubMedCentralPubMedCrossRefGoogle Scholar
- 38.Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D et al (2009) Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell line. Int J Cancer 124:36–45PubMedCentralPubMedCrossRefGoogle Scholar
- 41.Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E III, Zhang Y (2007) Activation of the PTEN/Mtor/STAT3 pathway in breast cancer stem-like cells in required for viability and maintenance. Proc Natl Acad Sci USA 104:16158–16163PubMedCentralPubMedCrossRefGoogle Scholar
- 44.Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H et al (2001) The ABC transporter Bcrp1/ABCG2 is expressed in wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034PubMedCrossRefGoogle Scholar
- 50.Lee CH, Chang YC, Chen CS, Tu SH, Wang YJ, Chen LC, Chang YJ, Wei PL, Chang HW, Chang CH et al (2011) Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells. Breast Cancer Res Treat 129:331–345PubMedCrossRefGoogle Scholar
- 56.Ahmed H, Guha P, Kaptan E, Bandyopadhyaya G (2011) Galectin-3: a potential target for cancer prevention. Trends Carbohydr Res 3:13–22Google Scholar